Overview Dividends

(IBRX) Immunitybio - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45256X1037

Immunotherapy, Vaccine, Cytokine, Cell Therapy, Bladder Cancer

EPS (Earnings per Share)

EPS (Earnings per Share) of IBRX over the last years for every Quarter: "2020-09": -0.2, "2020-12": -0.3, "2021-03": -0.21, "2021-06": -0.23, "2021-09": -0.22, "2021-12": -0.23, "2022-03": -0.26, "2022-06": -0.24, "2022-09": -0.28, "2022-12": -0.27, "2023-03": -0.27, "2023-06": -0.32, "2023-09": -0.19, "2023-12": -0.35, "2024-03": -0.2, "2024-06": -0.2, "2024-09": -0.1232, "2024-12": -0.08, "2025-03": -0.15, "2025-06": -0.1, "2025-09": -0.07,
EPS Growth (3y CAGR): 49.29%
EPS Trend (3y Corr): 83.2%
Last SUE: 0.49σ
Qual. Beats: 0

Revenue

Revenue of IBRX over the last years for every Quarter: 2020-09: 0.151, 2020-12: -0.147, 2021-03: 0.139, 2021-06: 0.339, 2021-09: 0.066, 2021-12: 0.39, 2022-03: 0.014, 2022-06: 0.035, 2022-09: 0.118, 2022-12: 0.073, 2023-03: 0.36, 2023-06: 0.041, 2023-09: 0.082, 2023-12: 0.139, 2024-03: 0.04, 2024-06: 1.047, 2024-09: 6.106, 2024-12: 7.552, 2025-03: 16.517, 2025-06: 26.425, 2025-09: 32.061,
Revenue Growth (3y CAGR): 814.04%
Revenue Trend (3y Corr): 88.4%
Last SUE: 0.06σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 96.5%
Value at Risk 5%th 137%
Relative Tail Risk -13.71%
Reward TTM
Sharpe Ratio -0.70
Alpha -76.58
Character TTM
Hurst Exponent 0.502
Beta 1.568
Beta Downside 1.431
Drawdowns 3y
Max DD 81.46%
Mean DD 54.33%
Median DD 61.15%

Description: IBRX Immunitybio November 11, 2025

ImmunityBio, Inc. (NASDAQ: IBRX) is a commercial-stage biotech firm focused on next-generation immunotherapies that harness the body’s innate immune mechanisms to fight cancer and infectious diseases. Its pipeline leverages cytokine-fusion proteins, DNA/vaccine vectors, and cell-therapy platforms, with the lead product Anktiva already FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and slated for further trials in both liquid and solid tumors.

Key performance indicators as of the latest quarter include a cash runway of approximately 12 months (~$150 M) and a 45 % YoY increase in R&D spend, reflecting accelerated trial enrollment. The biotech sector’s valuation is currently driven by a 7 % CAGR in immuno-oncology spend and a robust pipeline pipeline-to-approval conversion rate of ~12 % for early-stage biologics, both of which underpin ImmunityBio’s growth outlook. Strategic collaborations with the National Cancer Institute, Serum Institute of India, and BeiGene provide both development expertise and potential market access in emerging regions.

For a deeper, data-rich assessment of IBRX’s risk-adjusted upside, you might explore the analyst tools on ValueRay to complement this overview.

IBRX Stock Overview

Market Cap in USD 2,049m
Sub-Industry Biotechnology
IPO / Inception 2015-07-28
Return 12m vs S&P 500 -63.0%
Analyst Rating 4.60 of 5

IBRX Dividends

Currently no dividends paid

IBRX Growth Ratios

Metric Value
CAGR 3y -27.90%
CAGR/Max DD Calmar Ratio -0.34
CAGR/Mean DD Pain Ratio -0.51
Current Volume 11685.7k
Average Volume 8160.6k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-348.6m TTM) > 0 and > 6% of Revenue (6% = 4.95m TTM)
FCFTA -0.62 (>2.0%) and ΔFCFTA 56.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 329.9% (prev 1394 %; Δ -1064 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.62 (>3.0%) and CFO -319.7m > Net Income -348.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (946.6m) change vs 12m ago 35.62% (target <= -2.0% for YES)
Gross Margin 89.75% (prev -86.54%; Δ 176.3pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 18.69% (prev 2.01%; Δ 16.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.48 (EBITDA TTM -232.6m / Interest Expense TTM 100.2m) >= 6 (WARN >= 3)

Altman Z'' -31.16

(A) 0.52 = (Total Current Assets 329.5m - Total Current Liabilities 57.1m) / Total Assets 519.0m
(B) -7.06 = Retained Earnings (Balance) -3.66b / Total Assets 519.0m
warn (B) unusual magnitude: -7.06 — check mapping/units
(C) -0.56 = EBIT TTM -248.5m / Avg Total Assets 441.8m
(D) -7.43 = Book Value of Equity -4.24b / Total Liabilities 569.8m
Total Rating: -31.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.78

1. Piotroski 1.0pt
2. FCF Yield -16.73%
3. FCF Margin data missing
4. Debt/Equity -0.07
5. Debt/Ebitda 0.08
6. ROIC - WACC (= 410.9)%
7. RoE 62.78%
8. Rev. Trend 88.36%
9. EPS Trend 83.25%

What is the price of IBRX shares?

As of November 21, 2025, the stock is trading at USD 2.02 with a total of 11,685,732 shares traded.
Over the past week, the price has changed by +1.00%, over one month by -17.55%, over three months by -10.62% and over the past year by -58.56%.

Is IBRX a buy, sell or hold?

Immunitybio has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy IBRX.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IBRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 10.2 405%
Analysts Target Price 10.2 405%
ValueRay Target Price 1.5 -23.8%

IBRX Fundamental Data Overview November 17, 2025

Market Cap USD = 2.05b (2.05b USD * 1.0 USD.USD)
P/S = 24.8165
Beta = -0.057
Revenue TTM = 82.6m USD
EBIT TTM = -248.5m USD
EBITDA TTM = -232.6m USD
Long Term Debt = 500.8m USD (from longTermDebt, last quarter)
Short Term Debt = 7.32m USD (from shortTermDebt, last quarter)
Debt = 41.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.94b USD (2.05b + Debt 41.4m - CCE 153.7m)
Interest Coverage Ratio = -2.48 (Ebit TTM -248.5m / Interest Expense TTM 100.2m)
FCF Yield = -16.73% (FCF TTM -324.0m / Enterprise Value 1.94b)
FCF Margin = -392.5% (FCF TTM -324.0m / Revenue TTM 82.6m)
Net Margin = -422.3% (Net Income TTM -348.6m / Revenue TTM 82.6m)
Gross Margin = 89.75% ((Revenue TTM 82.6m - Cost of Revenue TTM 8.46m) / Revenue TTM)
Gross Margin QoQ = 87.12% (prev 99.49%)
Tobins Q-Ratio = 3.73 (Enterprise Value 1.94b / Total Assets 519.0m)
Interest Expense / Debt = 66.55% (Interest Expense 27.6m / Debt 41.4m)
Taxrate = 0.05% (-35.0k / -67.3m)
NOPAT = -248.3m (EBIT -248.5m * (1 - 0.05%)) [loss with tax shield]
Current Ratio = 5.77 (Total Current Assets 329.5m / Total Current Liabilities 57.1m)
Debt / Equity = -0.07 (negative equity) (Debt 41.4m / totalStockholderEquity, last quarter -569.8m)
Debt / EBITDA = 0.08 (negative EBITDA) (Net Debt -18.8m / EBITDA -232.6m)
Debt / FCF = 0.06 (negative FCF - burning cash) (Net Debt -18.8m / FCF TTM -324.0m)
Total Stockholder Equity = -555.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.17% (Net Income -348.6m / Total Assets 519.0m)
RoE = 62.78% (negative equity) (Net Income TTM -348.6m / Total Stockholder Equity -555.3m)
RoCE = 456.1% (negative capital employed) (EBIT -248.5m / Capital Employed (Equity -555.3m + L.T.Debt 500.8m))
RoIC = 422.5% (negative operating profit) (NOPAT -248.3m / Invested Capital -58.8m)
WACC = 11.56% (E(2.05b)/V(2.09b) * Re(11.79%) + (debt cost/tax rate unavailable))
Discount Rate = 11.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 26.59%
Fair Price DCF = unknown (Cash Flow -324.0m)
EPS Correlation: 83.25 | EPS CAGR: 49.29% | SUE: 0.49 | # QB: 0
Revenue Correlation: 88.36 | Revenue CAGR: 814.0% | SUE: 0.06 | # QB: 0

Additional Sources for IBRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle